[go: up one dir, main page]

MX2010005871A - Anticuerpos al antigeno de pcrv de pseudomonas aeruginosa. - Google Patents

Anticuerpos al antigeno de pcrv de pseudomonas aeruginosa.

Info

Publication number
MX2010005871A
MX2010005871A MX2010005871A MX2010005871A MX2010005871A MX 2010005871 A MX2010005871 A MX 2010005871A MX 2010005871 A MX2010005871 A MX 2010005871A MX 2010005871 A MX2010005871 A MX 2010005871A MX 2010005871 A MX2010005871 A MX 2010005871A
Authority
MX
Mexico
Prior art keywords
pseudomonas aeruginosa
antibodies
pcrv
pcrv antigen
antigen
Prior art date
Application number
MX2010005871A
Other languages
English (en)
Inventor
Christopher R Bebbington
Geoffrey T Yarranton
Kenneth Luehrsen
Mark Baer
Original Assignee
Kalobios Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kalobios Pharmaceuticals Inc filed Critical Kalobios Pharmaceuticals Inc
Publication of MX2010005871A publication Critical patent/MX2010005871A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1214—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Pseudomonadaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La presente invención provee anticuerpos de alta afinidad a la proteína de PcrV de Pseudomonas aeruginosa que tienen inmunogenicidad reducida cuando son administrados para tratar infecciones de Pseudomonas aeruginosa.
MX2010005871A 2007-11-30 2008-12-01 Anticuerpos al antigeno de pcrv de pseudomonas aeruginosa. MX2010005871A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US99167907P 2007-11-30 2007-11-30
PCT/US2008/085196 WO2009073631A2 (en) 2007-11-30 2008-12-01 Antibodies to the pcrv antigen of pseudomonas aeruginosa

Publications (1)

Publication Number Publication Date
MX2010005871A true MX2010005871A (es) 2010-06-09

Family

ID=40527381

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010005871A MX2010005871A (es) 2007-11-30 2008-12-01 Anticuerpos al antigeno de pcrv de pseudomonas aeruginosa.

Country Status (15)

Country Link
US (3) US8044181B2 (es)
EP (1) EP2220117A2 (es)
JP (1) JP5781765B2 (es)
KR (1) KR20100097719A (es)
CN (1) CN101910197B (es)
AU (1) AU2008333985B2 (es)
BR (1) BRPI0819598A2 (es)
CA (1) CA2706732A1 (es)
EA (1) EA201000903A1 (es)
IL (1) IL206036A0 (es)
MX (1) MX2010005871A (es)
NZ (1) NZ586357A (es)
SG (1) SG186017A1 (es)
WO (1) WO2009073631A2 (es)
ZA (1) ZA201003852B (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9453251B2 (en) 2002-10-08 2016-09-27 Pfenex Inc. Expression of mammalian proteins in Pseudomonas fluorescens
BRPI0513826A2 (pt) 2004-07-26 2010-06-22 Dow Global Technologies Inc processo para expressão de proteìna melhorada através de engenharia de cepa
US9580719B2 (en) * 2007-04-27 2017-02-28 Pfenex, Inc. Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins
WO2008134461A2 (en) * 2007-04-27 2008-11-06 Dow Global Technologies, Inc. Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins
WO2009088032A1 (ja) 2008-01-10 2009-07-16 Shionogi & Co., Ltd. ＰｃｒＶに対する抗体
JP2012516897A (ja) * 2009-02-04 2012-07-26 カロバイオス ファーマシューティカルズ インコーポレイティッド シュードモナス・エルギノーサ（ＰｓｅｕｄｏｍｏｎａｓＡｅｒｕｇｉｎｏｓａ）感染の治療のための抗生物質と抗体療法との組み合わせ
ES2529734T7 (es) * 2009-03-11 2015-08-11 Shionogi & Co., Ltd. Anticuerpo PcrV humanizado con actividad anti-pseudomonas
US8642039B2 (en) 2009-12-22 2014-02-04 Kalobios Pharmaceuticals, Inc. Method of treating a staphylococcus infection in a patient having a low-level pathogenic Pseudomonas aeruginosa infection
WO2012012571A1 (en) 2010-07-21 2012-01-26 Hans Zassenhaus Biolayer interferometry measurement of biological targets
RS57024B1 (sr) 2011-06-10 2018-05-31 Medimmune Ltd Anti-pseudomonas psl vezujući molekuli i njihova upotreba
BR112014011028B1 (pt) * 2011-11-07 2021-03-02 Medimmune, Llc anticorpo biespecífico, composição, e, uso da composição
AU2013224851B2 (en) 2012-03-02 2018-03-01 Ablynx Nv Pseudomonas aeruginosa PcrV binding single variable domain antibodies
AU2013341349A1 (en) * 2012-11-06 2015-05-21 Medimmune Limited Combination therapies using anti-Pseudomonas Psl and PcrV binding molecules
MX2017014002A (es) * 2015-05-01 2018-08-01 Inhibrx Lp Moléculas de direccionamiento del sistema de secreción tipo iii .
RU2021111382A (ru) 2015-07-16 2021-05-21 Инхибркс, Инк. Мультивалентные и мультиспецифические гибридные белки, связывающиеся с dr5
EP3452090A4 (en) 2016-05-05 2019-12-18 The Trustees of The University of Pennsylvania DNA ANTIBODY CONSTRUCTS FOR USE AGAINST PSEUDOMONAS AERUGINOSA
SG11202100663VA (en) * 2018-08-01 2021-02-25 Cephalon Inc Anti-cxcr2 antibodies and uses thereof
SG11202112462RA (en) * 2019-06-11 2021-12-30 Regeneron Pharma Anti-pcrv antibodies that bind pcrv, compositions comprising anti-pcrv antibodies, and methods of use thereof
CN114072145B (zh) * 2020-06-01 2024-06-11 北京三诺佳邑生物技术有限责任公司 特异性识别假单胞菌pcrv的抗体及其用途

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US108565A (en) * 1870-10-25 Improvement in snow-plows
US225552A (en) * 1880-03-16 Disintegrating-mill
US134098A (en) * 1872-12-17 Improvement in gage-cocks
GB8720833D0 (en) 1987-09-04 1987-10-14 Celltech Ltd Recombinant dna product
US5219998A (en) * 1990-06-04 1993-06-15 Levin Robert H Yeast-derived epidermal growth factor
GB9012995D0 (en) * 1990-06-11 1990-08-01 Celltech Ltd Multivalent antigen-binding proteins
ATE253593T1 (de) 1996-07-16 2003-11-15 Plueckthun Andreas Prof Dr Immunglobulin-superfamilie domainen und fragmente mit erhöhter löslichkeit
US7141393B2 (en) * 1996-12-26 2006-11-28 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Interleukin-18-receptor proteins
CA2318536C (en) * 1998-11-25 2009-11-17 Mcw Research Foundation, Inc. Method of and compositions for immunization with the pseudomonas v antigen
DE19918418C1 (de) * 1999-04-23 2000-10-19 Siegfried Mueller Pflanzvorrichtung mit Halterung
US20030235584A1 (en) * 2000-02-28 2003-12-25 Kloetzer William S. Method for preparing anti-MIF antibodies
US7494653B2 (en) * 2001-01-26 2009-02-24 Mcw Research Foundation, Inc. Method and compositions for immunization with the Pseudomonas V antigen
CA2374027A1 (en) * 2001-03-13 2002-09-13 The Minister Of National Defence Cloning, expression, sequencing, and functional enhancement of monoclonal scfv antibody against venezuelan equine encephalitis virus(vee)
EP1479695B1 (en) * 2003-05-14 2010-02-17 Kenta Biotech AG Human monoclonal antibody specific for lipopolysaccharides (LPS) of serotype IATS O6 of Pseudomonas aeruginosa
WO2005069970A2 (en) * 2004-01-20 2005-08-04 Kalobios, Inc. Antibody specificity transfer using minimal essential binding determinants
PT2343380T (pt) 2004-11-16 2019-09-18 Humanigen Inc Permuta de cassetes da região variável de imunoglobulina
CA2606576A1 (en) 2005-05-20 2006-11-23 Lonza Biologics Plc. High-level expression of recombinant antibody in a mammalian host cell
EP1726650A1 (en) 2005-05-27 2006-11-29 Universitätsklinikum Freiburg Monoclonal antibodies and single chain antibody fragments against cell-surface prostate specific membrane antigen
EP1906990B1 (en) 2005-07-05 2013-12-11 Baker Medical Research Institute Anticoagulation agent
WO2007096396A2 (en) 2006-02-22 2007-08-30 University Of Zurich Methods for treating autoimmune or demyelinating diseases
NO345476B1 (no) 2006-06-02 2021-02-22 Xoma Technology Ltd Bindingsproteiner for hepatocyttvekstfaktor (HGF)
JP5028635B2 (ja) 2006-06-21 2012-09-19 オンコセラピー・サイエンス株式会社 Ｆｚｄ１０に対する腫瘍標的化モノクローナル抗体とその使用

Also Published As

Publication number Publication date
NZ586357A (en) 2012-10-26
AU2008333985B2 (en) 2015-02-05
CN101910197B (zh) 2014-09-24
US8877191B2 (en) 2014-11-04
WO2009073631A2 (en) 2009-06-11
JP2011505381A (ja) 2011-02-24
US20090191186A1 (en) 2009-07-30
AU2008333985A1 (en) 2009-06-11
SG186017A1 (en) 2012-12-28
US20120020986A1 (en) 2012-01-26
EP2220117A2 (en) 2010-08-25
KR20100097719A (ko) 2010-09-03
EA201000903A1 (ru) 2011-02-28
BRPI0819598A2 (pt) 2017-05-09
IL206036A0 (en) 2010-11-30
JP5781765B2 (ja) 2015-09-24
CA2706732A1 (en) 2009-06-11
ZA201003852B (en) 2014-11-26
US8044181B2 (en) 2011-10-25
WO2009073631A3 (en) 2009-09-24
US20150030614A1 (en) 2015-01-29
CN101910197A (zh) 2010-12-08

Similar Documents

Publication Publication Date Title
MX2010005871A (es) Anticuerpos al antigeno de pcrv de pseudomonas aeruginosa.
PH12018502601A1 (en) Anti-b7-h3 antibodies and antibody drug conjugates
WO2019224716A8 (en) Antibodies specific for gucy2c and uses thereof
UA118332C2 (uk) Білок, що зв'язує антиген cd27l
TW200714290A (en) Anti-M-CSF antibody compositions having reduced levels of endotoxin
MX2018015277A (es) Anticuerpos anti-b7-h3 y conjugados de anticuerpo y farmaco.
UA92505C2 (ru) Композиции на основе антитела против cd3
MX2010003574A (es) Anticuerpos il-23.
UA105009C2 (uk) Композиції та способи, призначені для спрямованого впливу антитіл на білок с5 системи комплементу
CA2883095C (en) Antibody and protein formulations
PH12015500550A1 (en) Anti-notch1 nrr antibodies and methods using same
MX2009008430A (es) Anticuerpos anti-robo4 y sus usos.
BR112015009924A2 (pt) formulações de proteína imunoglobulina de domínio variável duplo estáveis
GEP20156390B (en) Antibody targeting through a modular recognition domain
UA112416C2 (uk) Антитіло до fap і способи його застосування
EP3702372A3 (en) Anti-cd40 human antibodies
EA201390145A1 (ru) Конъюгаты, частицы, композиции и связанные с ними способы
WO2017214458A3 (en) Anti-cd98 antibodies and antibody drug conjugates
WO2017214462A3 (en) Anti-cd98 antibodies and antibody drug conjugates
EP4372002A3 (en) Proximity-based sortase-mediated protein purification and ligation
CA2705357C (en) Formulations for taci-immunoglobulin fusion proteins
EA201101241A1 (ru) Лечение лейкозов и хронических миелопролиферативных болезней антителами к ерна3
MA32388B1 (fr) Immunomodulation par des inhibiteurs d'iap
TW200738751A (en) Anti-EphrinB2 antibodies and methods using same
WO2007106915A8 (en) Antibodies to egfl7 and methods for their use

Legal Events

Date Code Title Description
FG Grant or registration